Ming Zhan

List of Publications by Year
in descending order

34 papers	1,023 citations	394421 19 h-index	434195 31 g-index
34 all docs	34 docs citations	34 times ranked	1688 citing authors

#	Article	IF	Citations
1	Development and validation of a prognostic nomogram for gallbladder cancer patients after surgery. BMC Gastroenterology, 2022, 22, 200.	2.0	13
2	Yolk sac-derived Pdcd11-positive cells modulate zebrafish microglia differentiation through the NF-Î°B-TgfÎ²1 pathway. Cell Death and Differentiation, 2021, 28, 170-183.	11.2	9
3	The RNA methyltransferase NSUN6 suppresses pancreatic cancer development by regulating cell proliferation. EBioMedicine, 2021, 63, 103195.	6.1	45
4	LncRNA DIO3OS regulated by TGF-Î²1 and resveratrol enhances epithelial mesenchymal transition of benign prostatic hyperplasia epithelial cells and proliferation of prostate stromal cells. Translational Andrology and Urology, 2021, 10, 643-653.	1.4	16
5	Modulation of mTOR and epigenetic pathways as therapeutics in gallbladder cancer. Molecular Therapy - Oncolytics, 2021, 20, 59-70.	4.4	8
6	The use of an oxidative stress scoring system in prognostic prediction for kidney renal clear cell carcinoma. Cancer Communications, 2021, 41, 354-357.	9.2	3
7	In vivo Analysis of the Resistance of the Meshes to Escherichia coli Infection. Frontiers in Surgery, 2021, 8, 644227.	1.4	5
8	Upregulation of GBP1 in thyroid primordium is required for developmental thyroid morphogenesis. Genetics in Medicine, 2021, 23, 1944-1951.	2.4	13
9	TGF-Î²1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44. Cellular and Molecular Life Sciences, 2021, 78, 949-962.	5.4	46
10	Therapeutic Effects of 25-Hydroxyvitamin D on the Pathological Process of Benign Prostatic Hyperplasia: An In Vitro Evidence. Disease Markers, 2021, 2021, 1-12.	1.3	4
11	Glycochenodeoxycholate promotes the metastasis of gallbladder cancer cells by inducing epithelial to mesenchymal transition via activation of SOCS3/JAK2/STAT3 signaling pathway. Journal of Cellular Physiology, 2020, 235, 1615-1623.	4.1	12
12	Tamoxifen inhibits cell proliferation by impaired glucose metabolism in gallbladder cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 1599-1613.	3.6	10
13	miR-3613-5p enhances the metastasis of pancreatic cancer by targeting CDK6. Cell Cycle, 2020, 19, 3086-3095.	2.6	14
14	Long noncoding RNA PVT1 promotes tumor growth and predicts poor prognosis in patients with diffuse large Bâ€cell lymphoma. Cancer Communications, 2020, 40, 551-555.	9.2	7
15	Deoxycholic acid modulates the progression of gallbladder cancer through N6-methyladenosine-dependent microRNA maturation. Oncogene, 2020, 39, 4983-5000.	5.9	48
16	Variants in oxidative stress-related genes affect the chemosensitivity through Nrf2-mediated signaling pathway in biliary tract cancer. EBioMedicine, 2019, 48, 143-160.	6.1	20
17	PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR/CCL2 pathway. Journal of Experimental and Clinical Cancer Research, 2019, 38, 247.	8.6	56
18	TAMM41 is required for heart valve differentiation via regulation of PINK-PARK2 dependent mitophagy. Cell Death and Differentiation, 2019, 26, 2430-2446.	11.2	22

#	Article	IF	Citations
19	Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer. Nature Communications, 2019, 10, 5492.	12.8	54
20	Circular RNA circERBB2 promotes gallbladder cancer progression by regulating PA2G4-dependent rDNA transcription. Molecular Cancer, 2019, 18, 166.	19.2	71
21	PLZF inhibits proliferation and metastasis of gallbladder cancer by regulating IFIT2. Cell Death and Disease, 2018, 9, 71.	6.3	36
22	Elevated expression of NFE2L3 predicts the poor prognosis of pancreatic cancer patients. Cell Cycle, 2018, 17, 2164-2174.	2.6	33
23	Guided chemotherapy based on patientâ€derived miniâ€xenograft models improves survival of gallbladder carcinoma patients. Cancer Communications, 2018, 38, 1-9.	9.2	32
24	miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer. Scientific Reports, 2017, 7, 43109.	3.3	70
25	miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer. Cell Death and Disease, 2017, 8, e2770-e2770.	6.3	55
26	Epithelial-to-mesenchymal transition in gallbladder cancer: from clinical evidence to cellular regulatory networks. Cell Death Discovery, 2017, 3, 17069.	4.7	29
27	miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis. Cell Death and Disease, 2017, 8, e3129-e3129.	6.3	33
28	miR-92b-3p acts as a tumor suppressor by targeting Gabra3 in pancreatic cancer. Molecular Cancer, 2017, 16, 167.	19.2	92
29	Impact of diabetes mellitus on the survival of pancreatic cancer: a meta-analysis. OncoTargets and Therapy, 2016, 9, 1679.	2.0	12
30	The effects of buthionine sulfoximine on the proliferation and apoptosis of biliary tract cancer cells induced by cisplatin and gemcitabine. Oncology Letters, 2016, 11, 474-480.	1.8	30
31	miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1. Tumor Biology, 2016, 37, 10553-10562.	1.8	50
32	Phenylethyl isothiocyanate reverses cisplatin resistance in biliary tract cancer cells via glutathionylation-dependent degradation of Mcl-1. Oncotarget, 2016, 7, 10271-10282.	1.8	29
33	FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin <i>via</i> SHP dependent inhibition of Bcl-xL expression. Oncotarget, 2016, 7, 34617-34629.	1.8	20
34	NOX1 mediates chemoresistance via HIF1Î±/MDR1 pathway in gallbladder cancer. Biochemical and Biophysical Research Communications, 2015, 468, 79-85.	2.1	26